High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents

Evangelos Terpos, Meletios A. Dimopoulos, Vikas Shrivastava, Kim Leitzel, Dimitrios Christoulas, Magdalini Migkou, Maria Gavriatopoulou, Konstantinos Anargyrou, Peter Hamer, Efstathios Kastritis, Walter Carney, Allan Lipton

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Tissue inhibitor of metalloproteinase-1 (TIMP-1) was evaluated in the pre-treatment serum of 55 newly diagnosed patients with symptomatic myeloma. TIMP-1 was elevated in 47% of patients and correlated with lytic bone disease and increased bone resorption. Importantly, TIMP-1 correlated with ISS stage (p=0.005) and was an independent prognostic covariate for survival [HR: 1.003 (1-1.006), p=0.004] in these patients who were all treated with novel agents (bortezomib and/or IMiDs) during their disease course. Our study provides evidence that pre-treatment serum TIMP-1 is associated with advanced myeloma and suggests the further evaluation of this molecule to better determine its prognostic potential in MM.

Original languageEnglish (US)
Pages (from-to)399-402
Number of pages4
JournalLeukemia Research
Volume34
Issue number3
DOIs
StatePublished - Mar 1 2010

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Terpos, E., Dimopoulos, M. A., Shrivastava, V., Leitzel, K., Christoulas, D., Migkou, M., Gavriatopoulou, M., Anargyrou, K., Hamer, P., Kastritis, E., Carney, W., & Lipton, A. (2010). High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. Leukemia Research, 34(3), 399-402. https://doi.org/10.1016/j.leukres.2009.08.035